While the Keynote 585 trial (doublet chemo + pembrolizumab) failed overall, its small FLOT chemotherapy subgroup mirrored the positive results of the Matterhorn trial (FLOT + durvalumab). This suggests the choice of a less aggressive chemotherapy backbone, not the immunotherapy concept, was the critical factor in the trial's negative outcome.

The OlympiA study showed neoadjuvant olaparib plus durvalumab achieved an 80% pathologic complete response (pCR) rate in patients with T2N0 BRCA-mutated TNBC. This result, superior to what chemotherapy typically accomplishes, suggests a highly effective, chemotherapy-free future for this specific patient subgroup.

The practice-changing KEYNOTE-689 trial was open-label, meaning patients knew their treatment. This could introduce bias; patients on the standard care arm may have dropped out ("bailed"), while those on the pembrolizumab arm might have progressed, artificially making the rates of patients reaching surgery appear similar.

The discontinuation rate for pembrolizumab due to side effects was lower in the LITESPARK 022 trial compared to the earlier Keynote 564 trial (20%). This trend suggests that as clinicians gain more experience with immune checkpoint inhibitors, they are becoming more adept at managing immune-related adverse events, allowing more patients to complete their therapy.

Seven-year follow-up from the SOLO-1 trial shows a profound, sustained overall survival benefit for upfront olaparib maintenance. This advantage was not nullified even though 44% of the placebo group later received a PARP inhibitor, highlighting a critical, irreplaceable window of opportunity.

The BREAKAWAY trial's OS data is from a small, crossover-allowed study, making it hard to interpret alone. However, its findings are believable because they align with and reinforce a "building body of evidence" from larger trials like PROPEL and TALA PRO 2, which also show a survival benefit for PARP inhibitor combinations.

While KEYNOTE-905 showed dramatic survival benefits with neoadjuvant plus adjuvant EV-pembrolizumab, its design makes it impossible to isolate the benefit of each phase. The high (57%) pathologic complete response after neoadjuvant therapy alone suggests many patients may be overtreated with adjuvant cycles, risking unnecessary long-term toxicity like neuropathy.

In the LEAP-010 trial, the combination arm's higher efficacy was offset by significantly greater toxicity (67% vs 38% severe adverse events). This increased treatment burden likely limited sustained therapy and prevented patients from receiving subsequent treatments, ultimately nullifying any survival benefit from improved tumor response.

The LEAP-010 trial showed a combination therapy improved tumor response and progression-free survival but failed to improve overall survival, the ultimate measure of benefit. This highlights the risk of relying on surrogate endpoints, which can be misleading, especially when a treatment adds significant toxicity.